Table 2.

Global and microbiological success in modified intent-to-treat patients at the end of therapy according to specific ICU patient population and baseline characteristics

	Global success, n (%) [95% CI]	Microbiologicl success, n (%) [95% CI]
ICU patient population
Post-abdominal surgery	54/79 (68.4%) [56.9–78.4%]	55/80 (68.8%) [57.4–78.7%]
Elderly (≥65 years)	49/72 (68.1%) [56.0–78.6%]	54/75 (72.0%) [60.4–81.8%]
Renal insufficiency	44/58 (75.9%) [62.8–86.1%]	48/61 (78.7%) [66.3–88.1%]
Solid tumour	31/41 (75.6%) [59.7–87.6%]	32/42 (76.2%) [60.5–87.9%]
Hepatic insufficiency	18/25 (72.0%) [50.6–87.9%]	21/25 (84.0%) [63.9–95.5%]
Neutropaenic	6/12 (50.0%) [21.1–78.9%]	7/12 (58.3%) [27.7–84.8%]
Solid organ transplant recipient	3/8 (37.5%) [8.5–75.5%]	4/8 (50.0%) [15.7–84.3%]
Baseline pathogena
C. albicansb	64/86 (74.4%) [63.9–83.2%]	69/89 (77.5%) [67.4–85.7%]
C. glabrata	15/22 (68.2%) [45.1–86.1%]	15/22 (68.2%) [45.1–86.1%]
C. parapsilosis	10/15 (66.7%) [38.4–88.2%]	11/15 (73.3%) [44.9–92.2%]
C. tropicalis	4/11 (36.4%) [10.9–69.2%]	6/12 (50.0%) [21.1–78.9%]
Any non-albicansb	37/58 (63.8%) [50.1–76.0%]	40/59 (67.8%) [54.4–79.4%]
Baseline infection site
Bloodc,d	73/108 (67.6%) [57.9–76.3%]	81/112 (72.3%) [63.1–80.4%]
Other normally sterile site onlyd	34/46 (73.9%) [58.9–85.7%]	34/46 (73.9%) [58.9–85.7%]

Missing and unknown global or microbiological responses were excluded from these analyses.

^aExcluding patients with multiple pathogens at baseline.

^bThe differences between success rates in patients with C. albicans and non-albicans infections were not statistically significant (p 0.17 for global response, p 0.19 for microbiological response).

^cIncludes patients with baseline infection site, either blood only or blood and other normally sterile site.

^dThe differences between success rates in patients with candidaemia and without candidaemia were not statistically significant (p 0.44 for global response, p 0.84 for microbiological response).